Loading
Weekly paclitaxel controlled angiosarcoma in three quarters of patients at two months and produced responses in about one in five, establishing it as a standard first-line chemotherapy for this vascular sarcoma, especially of the scalp and face.
Phase 2 study of 30 patients with unresectable angiosarcoma treated with weekly paclitaxel 80 mg per square metre.
Non-progression at two months was 74 percent, objective response 19 percent, median progression-free survival 4 months and median overall survival 8 months; responses were more frequent in scalp and face angiosarcomas.
Weekly paclitaxel is a standard first-line option for angiosarcoma alongside doxorubicin, and it is also used with radiotherapy for unresectable scalp disease.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/